

## MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

**"OFFICIAL RECORD COPY"**

## Licensee

1. Central Medical Center &amp; Hospital

2. 1200 Centre Avenue  
Pittsburgh, Pennsylvania 15219In accordance with letter dated  
June 4, 1985,3. License number 37-16245-01 is amended in its  
entirety to read as follows:

4. Expiration date January 31, 1990

5. Docket or  
Reference No. 030-106566. Byproduct, source, and/or  
special nuclear material7. Chemical and/or physical  
form8. Maximum amount that licensee  
may possess at any one time  
under this license

- A. Any byproduct material  
listed in Groups I and  
II of Schedule A, Section  
35.100 of 10 CFR 35
- B. Any byproduct material  
listed in Group III of  
Schedule A, Section  
35.100 of 10 CFR 35
- C. Xenon 133

- A. Any radiopharmaceutical  
listed in Groups I and  
II of Schedule A, Section  
35.100 of 10 CFR 35
- B. Any form listed in Group  
III of Schedule A, Section  
35.100 of 10 CFR 35
- C. Gas or gas in solution  
that is the subject of  
an active (i.e., not  
withdrawn or terminated)  
"New Drug Application"  
(NDA) approved by FDA  
or an active (i.e., not  
withdrawn, terminated or  
on "clinical hold")  
"Notice of Claimed In-  
vestigational Exemption  
for a New Drug" (IND)  
that has been accepted  
by FDA

- A. As necessary for uses  
authorized in Subitem  
9.A.
- B. 2 curies of each  
byproduct material  
authorized in Subitem 6.B.
- C. 300 millicuries

## 9. Authorized use

- A. Any diagnostic procedure listed in Groups I and II of Schedule A, Section 35.100, Title 10, Code of Federal Regulations.
- B. Preparation and use of radiopharmaceuticals for any diagnostic procedure listed in Group III of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
- C. Blood flow and pulmonary function studies.

8507290276 850627  
REG1 LIC30  
37-16245-01 PDR

ML10

MATERIALS LICENSE  
SUPPLEMENTARY SHEET

License number

37-16245-01

Docket or Reference number

030-10656

Amendment No. 09

(continued)

## CONDITIONS

10. Licensed material shall be used only at Central Medical Center & Hospital, 1200 Centre Avenue, Pittsburgh, Pennsylvania.
11. The licensee shall comply with the provisions of Title 10, Chapter 1, Code of Federal Regulations, Part 19, "Notices, Instructions, and Reports to Workers; Inspections" and Part 20, "Standards for Protection Against Radiation."
12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:
- Morris Zachary Gardner, M.D.      Groups I, II and III  
Xenon 133
- Richard S. Gordon, M.D.      Groups I, II and III  
Xenon 133
13. Licensed material shall be used in accordance with the provisions of Section 35.14(b)(c)(e) and (f) of Title 10, Code of Federal Regulations.
14. For a period not to exceed sixty (60) days in any calendar year, a visiting physician is authorized to use licensed material for human use under the terms of this license, provided the visiting physician:
- (a) Has the prior written permission of the hospital's Administrator and its Medical Isotopes Committee, and
  - (b) Is specifically named as a user on a Nuclear Regulatory Commission license authorizing human use, and
  - (c) Performs only those procedures for which he is specifically authorized by a Nuclear Regulatory Commission license.
- The licensee shall maintain for the inspection by the Commission, copies of the written permission specified in subitem (a) above and of the license(s) specified in subitems (b) and (c) above. These records shall be maintained for five (5) years from the time the licensee grants its permission under subitem (a) above.
15. The licensee is authorized to hold radioactive material with a physical half-life of less than 65 days for decay-in-storage before disposal in ordinary trash provided:
- A. Radioactive waste to be disposed of in this manner shall be held for decay a minimum of ten (10) half-lives.
  - B. Prior to disposal as normal waste, radioactive waste shall be monitored to determine that its radioactivity cannot be distinguished from background with typical low-level laboratory survey instruments. All radiation labels will be removed or obliterated.
  - C. Generator columns shall be segregated so that they may be monitored separately to ensure decay to background levels prior to disposal.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License number

37-16245-01

Docket or Reference number

030-10656

Amendment No. 09

(continued)

**CONDITIONS**

16. The licensee may use the Calicheck device for performing linearity tests of the dose calibrator in accordance with the procedures in the Calcorp, Inc. Manual dated March 2, 1982.
17. The Licensee may use the Lineator device for doing linearity tests of his dose calibrator provided he follows the procedures in the Atomic Products Corporation Lineator Instructions Manual dated June 20, 1983.
18. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in application dated May 18, 1984, ALARA Program contained in letter dated November 7, 1984 and letter dated June 4, 1985. The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.



For the U.S. Nuclear Regulatory Commission

Original Signed By:

John E. Glenn

By

Nuclear Materials and Safeguards Branch  
Region I  
King of Prussia, Pennsylvania 19406

Date JUN 27 1985